Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.43 |
| ▸ | NQO2 | P16083 | 5/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7131312 | 1.00 | DRD2 (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL13221540 | 1.00 | DRD2 (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL14761632 | 0.95 | MTNR1A (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL16510284 | 0.95 | MTNR1A (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL7073014 | 0.95 | MTNR1A (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL7076288 | 0.93 | MAPT (0.43) | DRD2DRD1DRD5DRD3ESR2 | |
| SCHEMBL7076293 | 0.93 | MAPT (0.43) | DRD2DRD1DRD5DRD3ESR2 | |
| SCHEMBL7075532 | 0.88 | MAPT (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL7075529 | 0.88 | MAPT (0.43) | DRD2DRD1DRD5DRD3MTNR1A | |
| SCHEMBL14137057 | 0.83 | ESR2 (0.42) | ESR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | DRD2 283/4885DRD1 648/4885DRD5 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.